Clinical Trial

NAL ER IPF Respiratory Function and Safety Study

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-04
notable Enrollment reduced: 10 -> 9 participants 2026-08-04
notable Primary completion pushed: 2026-04 -> 2026-06-30 2026-04-10
minor Completion pushed: 2026-04 -> 2026-06-30 2026-04-10
Trial Details
NCT Number NCT07036029
Lead Sponsor Trevi Therapeutics
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 9 participants
Start Date 2025-08-21
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03